Bio-Path Holdings, Inc. (BPTH)
Bio-Path Holdings, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Bellaire, TX, US. The stock last traded at $0.04, down 3.69% on the session, giving a market capitalisation of $336,504. On trailing twelve-month figures it carries a trailing P/E of -0.05, a net margin of 0.0%. Its beta of -0.50 implies it has historically moved less than the broad market.
Bio-Path Holdings, Inc. is a U.S.-based pharmaceutical company focused on developing RNAi nanoparticle drugs for oncology, with programs spanning both clinical and preclinical stages. Its innovative product development is centered around the DNAbilize platform, a drug delivery and antisense technology that employs a P-ethoxy modified deoxyribonucleic acid (DNA) backbone. This modification is specifically engineered to shield the DNA from premature degradation. The company's lead drug candidate, prexigebersen, is presently in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. Additionally, Bio-Path is advancing Liposomal Bcl-2 for refractory/relapsed lymphoma and chronic lymphocytic leukemia. Another promising asset, Liposomal STAT3, is in preclinical development, targeting pancreatic cancer, non-small cell lung cancer, and AML. Furthermore, prexigebersen-A is under development for various solid tumors. Bio-Path Holdings, Inc., founded in 2007, is headquartered in Bellaire, Texas.
Bio-Path Holdings, Inc. is most often compared with the following Healthcare names: